Welcome to the dedicated Spotlight On Policy page, your central resource for curated, expert-driven coverage of pharmaceutical and health system policy across the United States, the United Kingdom, Europe, and the wider global landscape. US Policy updates News What do midterms mean for Trump's pharma and health agenda? As Democrats flip the Senate and House in a blue tsunami, we look at Trump's health and pharma policies that will likely see scrutiny and pushback. News HHS doubles down on controversial peptides plan HHS unveils an enforcement holiday to manufacture of unapproved peptides - before the FDA decides if they should be allowed in compounded medicines. News US Treasury proposes curbs on Chinese biotech deals China has emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could slam the brakes on future deals. News Despite US policy changes, drug prices stay stubbornly high US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access. more EU Policy updates News German sites added to Europe's cardiometabolic R&D network The BioInnovation Institute (BII) has expanded a European network to develop drugs for cardiometabolic diseases and launch new biotechs into Germany. News Sanofi escapes fine in EU mismarketing case Sanofi will not be fined for disparaging an influenza vaccine sold by rival CSL in a marketing campaign, according to the European Commission. Market Access One year after MFN: How US policy is reshaping the global ph... Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards MFN pricing. Market Access Beyond Market Access: Why healthcare-system understanding is... Healthcare-system literacy, and the ability to contribute to system shaping, must become part of how healthcare leaders make decisions. more UK Policy updates News UK pilots shorter NICE appraisal for new medicines NICE and NHS England are piloting a shorter initial assessment process for promising new medicines, aiming to slash times from 12 to six months. News UK backs start-up Potential Sciences' AI-powered drug hunt UK start-up Potential Sciences emerged from stealth today with a sizeable seed funding round and an ambition to transform drug discovery with AI. News AbbVie invests £120m in UK expansion AbbVie has pledged another £120 million to the UK, reinforcing the country's recovery as a pharma industry investment hotspot. News UK budget includes £1bn biopharma investment package UK Chancellor John Healey's first Budget speech included a £1bn-plus industry investment package at sites in Manchester, Oxford, and Loughborough. more
News What do midterms mean for Trump's pharma and health agenda? As Democrats flip the Senate and House in a blue tsunami, we look at Trump's health and pharma policies that will likely see scrutiny and pushback.
News HHS doubles down on controversial peptides plan HHS unveils an enforcement holiday to manufacture of unapproved peptides - before the FDA decides if they should be allowed in compounded medicines.
News US Treasury proposes curbs on Chinese biotech deals China has emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could slam the brakes on future deals.
News Despite US policy changes, drug prices stay stubbornly high US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.
News German sites added to Europe's cardiometabolic R&D network The BioInnovation Institute (BII) has expanded a European network to develop drugs for cardiometabolic diseases and launch new biotechs into Germany.
News Sanofi escapes fine in EU mismarketing case Sanofi will not be fined for disparaging an influenza vaccine sold by rival CSL in a marketing campaign, according to the European Commission.
Market Access One year after MFN: How US policy is reshaping the global ph... Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards MFN pricing.
Market Access Beyond Market Access: Why healthcare-system understanding is... Healthcare-system literacy, and the ability to contribute to system shaping, must become part of how healthcare leaders make decisions.
News UK pilots shorter NICE appraisal for new medicines NICE and NHS England are piloting a shorter initial assessment process for promising new medicines, aiming to slash times from 12 to six months.
News UK backs start-up Potential Sciences' AI-powered drug hunt UK start-up Potential Sciences emerged from stealth today with a sizeable seed funding round and an ambition to transform drug discovery with AI.
News AbbVie invests £120m in UK expansion AbbVie has pledged another £120 million to the UK, reinforcing the country's recovery as a pharma industry investment hotspot.
News UK budget includes £1bn biopharma investment package UK Chancellor John Healey's first Budget speech included a £1bn-plus industry investment package at sites in Manchester, Oxford, and Loughborough.
